Quality of life during the first 6 months of interferon-β treatment in patients with MS
To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile. IFN-beta has been shown to have ben...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2000-10, Vol.6 (5), p.338-342 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 342 |
|---|---|
| container_issue | 5 |
| container_start_page | 338 |
| container_title | Multiple sclerosis |
| container_volume | 6 |
| creator | ARNOLDUS, J. H. A KILLESTEIN, J PFENNINGS, Lema JELLES, B UITDEHAAG, B. M. J POLMAN, C. H |
| description | To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile.
IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far.
Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects.
During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P |
| doi_str_mv | 10.1191/135245800678827932 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72408648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72408648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c291t-62387992872ebcf30e34a1307b07490b2bd86c01d19b6cf01ea44215ac58634b3</originalsourceid><addsrcrecordid>eNqF0M1KXTEQB_BQlPrVF3BRspDuTp1JcvKxLGK1YClihe4OObmJN-V83CY5iK_lg_SZjHjBhQtnM8Pwm1n8CTlG-Ipo8BR5y0SrAaTSminD2Qeyj0KpBoyCnTpX0FTR7pGDnP8CgFK8_Uj2EEGKWvvkz_Vih1ge6BzoEIOnqyXF6Y6WtachplyopOM8lXV-FnEqPgWf5qn5_0hL8raMfip1Tze2xDpmeh_Lmv68OSK7wQ7Zf9r2Q3L7_fz32WVz9evix9m3q8Yxg6WRjGtlDNOK-d4FDp4LixxUD0oY6Fm_0tIBrtD00gVAb4Vg2FrXaslFzw_Jl5e_mzT_W3wu3Riz88NgJz8vuVNMgJZCvwtRKWZAyArZC3Rpzjn50G1SHG166BC65-C7t8HXo8_b70s_-tXryTbpCk62wGZnh5Ds5GJ-dS1HxSR_Ag1niYI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17729046</pqid></control><display><type>article</type><title>Quality of life during the first 6 months of interferon-β treatment in patients with MS</title><source>MEDLINE</source><source>SAGE Complete</source><creator>ARNOLDUS, J. H. A ; KILLESTEIN, J ; PFENNINGS, Lema ; JELLES, B ; UITDEHAAG, B. M. J ; POLMAN, C. H</creator><creatorcontrib>ARNOLDUS, J. H. A ; KILLESTEIN, J ; PFENNINGS, Lema ; JELLES, B ; UITDEHAAG, B. M. J ; POLMAN, C. H</creatorcontrib><description>To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile.
IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far.
Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects.
During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P<0.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F(1,24)=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL.
Our findings suggest that IFN-beta therapy has an impact on QoL of MS patients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-beta is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects. Multiple Sclerosis (2000) 6 338 - 342</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1191/135245800678827932</identifier><identifier>PMID: 11064444</identifier><language>eng</language><publisher>London: Arnold</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Adjuvants, Immunologic - adverse effects ; b-Interferon ; Biological and medical sciences ; Emotions ; Follow-Up Studies ; Health Status ; Humans ; Immunomodulators ; Interferon beta-1a ; Interferon beta-1b ; Interferon-beta - administration & dosage ; Interferon-beta - adverse effects ; Longitudinal Studies ; Medical sciences ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - psychology ; Neurology ; Pharmacology. Drug treatments ; Quality of Life</subject><ispartof>Multiple sclerosis, 2000-10, Vol.6 (5), p.338-342</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c291t-62387992872ebcf30e34a1307b07490b2bd86c01d19b6cf01ea44215ac58634b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1531726$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11064444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ARNOLDUS, J. H. A</creatorcontrib><creatorcontrib>KILLESTEIN, J</creatorcontrib><creatorcontrib>PFENNINGS, Lema</creatorcontrib><creatorcontrib>JELLES, B</creatorcontrib><creatorcontrib>UITDEHAAG, B. M. J</creatorcontrib><creatorcontrib>POLMAN, C. H</creatorcontrib><title>Quality of life during the first 6 months of interferon-β treatment in patients with MS</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile.
IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far.
Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects.
During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P<0.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F(1,24)=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL.
Our findings suggest that IFN-beta therapy has an impact on QoL of MS patients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-beta is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects. Multiple Sclerosis (2000) 6 338 - 342</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Adjuvants, Immunologic - adverse effects</subject><subject>b-Interferon</subject><subject>Biological and medical sciences</subject><subject>Emotions</subject><subject>Follow-Up Studies</subject><subject>Health Status</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interferon beta-1a</subject><subject>Interferon beta-1b</subject><subject>Interferon-beta - administration & dosage</subject><subject>Interferon-beta - adverse effects</subject><subject>Longitudinal Studies</subject><subject>Medical sciences</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - psychology</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of Life</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0M1KXTEQB_BQlPrVF3BRspDuTp1JcvKxLGK1YClihe4OObmJN-V83CY5iK_lg_SZjHjBhQtnM8Pwm1n8CTlG-Ipo8BR5y0SrAaTSminD2Qeyj0KpBoyCnTpX0FTR7pGDnP8CgFK8_Uj2EEGKWvvkz_Vih1ge6BzoEIOnqyXF6Y6WtachplyopOM8lXV-FnEqPgWf5qn5_0hL8raMfip1Tze2xDpmeh_Lmv68OSK7wQ7Zf9r2Q3L7_fz32WVz9evix9m3q8Yxg6WRjGtlDNOK-d4FDp4LixxUD0oY6Fm_0tIBrtD00gVAb4Vg2FrXaslFzw_Jl5e_mzT_W3wu3Riz88NgJz8vuVNMgJZCvwtRKWZAyArZC3Rpzjn50G1SHG166BC65-C7t8HXo8_b70s_-tXryTbpCk62wGZnh5Ds5GJ-dS1HxSR_Ag1niYI</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>ARNOLDUS, J. H. A</creator><creator>KILLESTEIN, J</creator><creator>PFENNINGS, Lema</creator><creator>JELLES, B</creator><creator>UITDEHAAG, B. M. J</creator><creator>POLMAN, C. H</creator><general>Arnold</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Quality of life during the first 6 months of interferon-β treatment in patients with MS</title><author>ARNOLDUS, J. H. A ; KILLESTEIN, J ; PFENNINGS, Lema ; JELLES, B ; UITDEHAAG, B. M. J ; POLMAN, C. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c291t-62387992872ebcf30e34a1307b07490b2bd86c01d19b6cf01ea44215ac58634b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Adjuvants, Immunologic - adverse effects</topic><topic>b-Interferon</topic><topic>Biological and medical sciences</topic><topic>Emotions</topic><topic>Follow-Up Studies</topic><topic>Health Status</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interferon beta-1a</topic><topic>Interferon beta-1b</topic><topic>Interferon-beta - administration & dosage</topic><topic>Interferon-beta - adverse effects</topic><topic>Longitudinal Studies</topic><topic>Medical sciences</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - psychology</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ARNOLDUS, J. H. A</creatorcontrib><creatorcontrib>KILLESTEIN, J</creatorcontrib><creatorcontrib>PFENNINGS, Lema</creatorcontrib><creatorcontrib>JELLES, B</creatorcontrib><creatorcontrib>UITDEHAAG, B. M. J</creatorcontrib><creatorcontrib>POLMAN, C. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ARNOLDUS, J. H. A</au><au>KILLESTEIN, J</au><au>PFENNINGS, Lema</au><au>JELLES, B</au><au>UITDEHAAG, B. M. J</au><au>POLMAN, C. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life during the first 6 months of interferon-β treatment in patients with MS</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>6</volume><issue>5</issue><spage>338</spage><epage>342</epage><pages>338-342</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile.
IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far.
Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects.
During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P<0.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F(1,24)=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL.
Our findings suggest that IFN-beta therapy has an impact on QoL of MS patients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-beta is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects. Multiple Sclerosis (2000) 6 338 - 342</abstract><cop>London</cop><pub>Arnold</pub><pmid>11064444</pmid><doi>10.1191/135245800678827932</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2000-10, Vol.6 (5), p.338-342 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72408648 |
| source | MEDLINE; SAGE Complete |
| subjects | Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - adverse effects b-Interferon Biological and medical sciences Emotions Follow-Up Studies Health Status Humans Immunomodulators Interferon beta-1a Interferon beta-1b Interferon-beta - administration & dosage Interferon-beta - adverse effects Longitudinal Studies Medical sciences Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - psychology Neurology Pharmacology. Drug treatments Quality of Life |
| title | Quality of life during the first 6 months of interferon-β treatment in patients with MS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A38%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20during%20the%20first%206%20months%20of%20interferon-%CE%B2%20treatment%20in%20patients%20with%20MS&rft.jtitle=Multiple%20sclerosis&rft.au=ARNOLDUS,%20J.%20H.%20A&rft.date=2000-10-01&rft.volume=6&rft.issue=5&rft.spage=338&rft.epage=342&rft.pages=338-342&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1191/135245800678827932&rft_dat=%3Cproquest_cross%3E72408648%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17729046&rft_id=info:pmid/11064444&rfr_iscdi=true |